Use of the 1.5T Elekta Unity MR-Linac was associated with reduced rates of erectile dysfunction at 6, 12, and 18 months in ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...

Pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or ...

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients who are newly diagnosed with ...

Panelists discuss how medication adherence significantly impacts chronic myeloid leukemia (CML) treatment outcomes, with research showing even small differences between 90% and 95% adherence to ...

Identity and Independence: Many AYAs are in a developmental stage where they are gaining autonomy. A cancer diagnosis can ...

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary ...